Medlab Clinical (ASX.MDC) is a research and development facility centering development in new therapeutics for chronic diseases.
Chronic diseases present a significant global unmet need, to which Medlab's core activities focuses on:
1/. late stage trials for non-opioid analgesics,
2/. sub micron delivery platforms for small molecules, and
3/. adjuvant therapies targeting improvement in the microbiome.
Medlab is now at a stage where it seeks partnering and out-licence opportunities.
Chronic diseases present a significant global unmet need, to which Medlab's core activities focuses on:
1/. late stage trials for non-opioid analgesics,
2/. sub micron delivery platforms for small molecules, and
3/. adjuvant therapies targeting improvement in the microbiome.
Medlab is now at a stage where it seeks partnering and out-licence opportunities.
Ticker:
MDC
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2012
Main Therapeutic Focus:
Oncology
Lead Product in Development:
NanaBis™
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
